Sunzen Biotech Berhad has undergone significant business transformation and growth in recent years. Here are some key investment highlights to help you better understand the future prospects of this company.

Exiting from Animal Health Business. As of the latest record (FY2022), the animal health business accounted for 6.01% of the annual revenue but incurred a pre-tax loss of RM4.67 million. On 8 April 2024, Sunzen announced the termination of this business, which is expected to significantly improve the company's profitability. Following the complete divestment, the company's net profit margin is expected to see substantial improvement.

At the end of 2022, Sunzen acquired a stake in Xmegami, providing OEM services for the latter's products (aesthetic products) and thus entering the B2C ecosystem. On 6 May 2024, Sunzen proposed to acquire a 70% stake in Eye Nation Medical Sdn. Bhd. (ENM) for RM6.37 million, entering the healthcare sector and further improving the ecosystem. The acquisition is expected to be completed in Q3 2024, with related contributions reflected in Q4 2024 results.